tion (AMI) is the major cause of morbidity and mortality in humans and is a growing global health problem. Heart transplantation is currently the only long-term solution but is complicated by host immune rejection and compounded by the fact that demand continually outstrips the availability of donor hearts. Therefore, a clinical imperative is the replacement of damaged cardiac muscle and blood vessels within the injured organ. In this regard, focus has shifted toward providing a source of exogenous cells as a surrogate or precursor for cardiovascular cell types, and as a consequence, cell implantation has moved rapidly from bench to bedside. Preclinical studies in animal models have reported significant improvements in cardiac function after cell therapy, 1 which has resulted in a number of clinical trials attempting to regenerate heart muscle after AMI through the use of a variety of autologous cells. Such trials have largely used stem cells derived from bone marrow or skeletal myoblasts. Metaanalysis of all randomized, placebo-controlled bone marrow trials indicates a net overall improvement in left ventricular ejection fraction (LVEF) of around 3%. 2 In the REPAIR-AMI study, the largest and most extensively controlled trial to date, a significant Ն5% increase in LVEF following bone marrow treatment was observed in patients with a preinfusion LVEF of Յ49%. 3 This increase compares favorably with that following early reperfusion therapy in patients with AMI, either via angioplasty or thrombolysis, and may potentially be improved with optimization of starting cell number, timing and route of cell delivery (intracoronary, intramyocardial versus systemic), single versus repeat dosing, and, importantly, insight into the most efficacious bone marrow cell type. It is often postulated that the beneficial effects following bone marrow infusion primarily arise from the paracrine action of secreted factors from the donor cells, and there is currently no consensus that bone marrowderived cells can differentiate to contribute new muscle efficiently. The MAGIC trial, of high and low doses of skeletal myoblasts injected into the myocardium of patients with AMI undergoing surgery, revealed no significant differences in LVEF following cell treatment or placebo, and the trial was ultimately abandoned because of a higher incidence of ventricular arrhythmias in the myoblast groups than in control patients. 4, 5 Despite the prevalence of clinical trials, there continues to be an urgent need to identify the most promising cardiovascular stem cells for achieving therapeutic regeneration. With the emerging paradigm that fetal programming of stem and progenitor cell types might be extrapolated to the adult disease setting, embryonic stem cells (ESCs) have been identified as a potential therapeutic source for heart repair. In early rodent ESC transplantation experiments, in which the cellular graft was heterogeneous and included undifferentiated cells, the end result was often tumorigenic. 6 As a result recent efforts have shifted toward directing ESCs to form cardiomyocytes, offering both a prospective source of cells to model human heart disease and establishing a committed cardiogenic stage with which to pursue valid cell transplantation strategies.
Human (h)ESC-derived cardiomyocytes resemble immature human fetal cardiomyocytes by multiple criteria including electrophysiology, calcium handling, force generation, contractile protein expression, and myofibrillar structure, and because hESC-derived cardiomyocytes have the potential to engraft into surgical models of heart disease, they have been considered for cardiomyocyte replacement therapy (reviewed elsewhere 7 ). Despite encouraging advances, the use of hESC-derived cardiomyocytes for basic developmental research and large-scale applications, such as highthroughput screening, toxicology testing, and preclinical animal studies, has been severely hampered by poor yield and sorting from typically heterogeneous cultures.
To circumvent this bottleneck, investigators have resorted to establishing genetically engineered ESC lines either by transgenic modification in mouse ESCs or viral transduction in human ESCs with selection cassettes under the control of cardiac-specific gene promoters such as Nkx2.5 8 and ␣MHC. 9 Thus, cardiomyocytes can be selected from differentiated heterogeneous cultures on the basis of either reporter gene expression (␤-galactosidase substrate or enhanced green fluorescent protein/yellow fluorescent protein fluorescence) by flow cytometry or via a drug selectable marker. Although this is a valid approach for basic research into cardiac differentiation, it is not conducive to clinical translation. The use of viruses in the human setting is compromised by the risk of adverse insertional events (potentially impacting on unrelated gene function) and the longer culture periods to establish stable lines for selection raises the distinct possibility of phenotypic drift ("evolution in a dish"). Ideally, therefore, one would wish to enrich for ESC-derived cardiomyocytes directly, using a suitable naturally occurring marker (Figure) . Until now, such markers have not been extensively elucidated, and there is a lack of even the basic insight into specific cell surface proteins that may demarcate cardiomyocyte progenitors.
In this issue of Circulation Research, Hidaka and colleagues 10 identify the cellular prion protein (PrP), classically associated with fatal neurological disorders in humans such as sporadic Creutzfeldt-Jakob disease, as an effective surface marker for isolating cardiomyocytes. 11 Following earlier experiments to determine arrays of cardiogenesis-associated factors expressed in ESCs, [11] [12] [13] the Prnp gene, which encodes PrP, was found to be highly expressed in cardiomyocyte-rich embryoid bodies (EBs). Hidaka et al show that Prnp is expressed in ESC derived cardiomyocytes and reveal not only that Prp ϩ flow-sorted ESCs differentiate from primitive to definitive cardiomyocytes but also that, functionally, they are analogous to "working cardiomyocytes" at the level of action potentials and ␤-adrenergic response. 11 A key finding was that approximately 90% of the Prp ϩ cells differentiated into cardiac troponin (cTn)T ϩ and cTnI ϩ cardiomyocytes with atrial or ventricular identity. As such, the efficient generation of cardiomyocytes with characteristics of chamber myocardium is highly significant when considering cardiac repair after AMI. The authors then used platelet-derived growth factor receptor (PDGFR)␣ as a secondary marker to facilitate earlier isolation of cardiomyocyte progenitors. The Prp ϩ PDGFR␣ ϩ fraction, denoted PRa, was found to express cardiac marker genes at day 5 of EB differentiation and, as such, represents the earliest known cardiomyogenic population. Of perhaps even greater significance, the PRa population contained bipotential cardiac and smooth muscle progenitors, consistent with previous studies in the developing mouse embryo 8 and hESC-derived EBs. 13 Extrapolating in vivo, Prnp mRNA was localized to cardiac mesoderm in late-bud-stage mouse embryos and PrP protein expression observed in cardiac crescent at head fold stages. PDGFR␣ was shown to be expressed in cardiac mesoderm and a time course of flow cytometry of PRa cells, isolated from mouse embryos, revealed 2 distinct subfractions: sarcomeric myosin heavy chain (Myhc) ϩ nascent cardiomyocytes, as well as Myhc cardiomyogenic progenitors. Finally, the authors show that cultured PRa cells from mouse embryos at embryonic day 7.5 differentiate into either cardiac or smooth muscle cells, whereas those isolated from embryonic day 8.0 differentiate exclusively into cardiomyocytes. These findings are consistent with the EB data but, more importantly, inform on the narrow window of commitment of PRa cells to the cardiomyocyte lineage in vivo and provide insight regarding cardiomyocyte specification during development.
Arguably, the PRa cells described here are the most interesting and potentially translational population, yet their identification by the dual surface markers Prp and PDGFR␣ may complicate selection and impair high-throughput enrichment. Importantly, in future studies, it will be critical to ensure that Prp is unequivocally 100% selective for committed cardiac progenitors in a heterogeneous population, because inclusion of any undifferentiated ESCs in a donor graft 
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will result in teratoma formation. Moreover, it remains to be determined whether the human ortholog of cellular PrP marks both cardiomyocyte progenitors and bona fide cardiomyocytes, in an analogous manner to that revealed here in mouse, for the ultimate validation of Prp as a tool for therapeutic use. These caveats aside, the key finding that Prp specifically identifies a cardiomyogenic cell population derived from ESCs without genetic modification is certainly a major step in the right direction toward the natural purification of a source of cardiac cells to facilitate basic heart development studies, cell transplantation, and myocardial repair in adult cardiac disease.
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